GMMMG Formulary Chapters
The GMMMG formulary ensures that patients receive seamless care across the primary-secondary care interface and reduces the need for switching programmes. Adherence to the formulary is strongly recommended by GMMMG and this formulary supersedes all local formularies. The formulary is applicable to new initiations and should meet the needs of the majority of adult patients.
NICE approved medicines:
All medicines recommended for use in the NHS in a NICE Technology Assessment are approved for use in Greater Manchester.
The documents on this page will be subject to updates. Please refresh your browser to ensure that you are looking at the latest versions. If you have any requests, changes or removals please go to the Formulary Requests section.
At the start of each chapter the contents section hyperlinks to the various subsections within that chapter.
The GM Formulary includes medicines and technologies for use in adult patients only. For information relating to prescribing in children prescribers should refer to the BNF and BNFc.
The GMMMG Formulary lists products by generic drug name. For some drugs, branded generics may offer a more economical means of procurement in Primary Care. In this instance the brand with the lowest acquisition cost and greatest ease of acquisition should be prescribed according to local choice.
|Document Title||Issue Date||Review Date||Status|
|1. Gastro-intestinal system||20230331 Mar 2023||Final version 7.7|
|2. Cardiovascular system||20221231 Dec 2022||Final version 7.12|
|3. Respiratory system||20221231 Dec 2022||Final version 8.6|
|4. Central nervous system||20221231 Dec 2022||Final Version 9.14|
|5. Infections||20221001 Sep 2022||Final version 7.4|
|6. Endocrine system||20230331 Mar 2023||Final version 9.17|
|7. Obstetrics, gynaecology and urinary–tract disorders||20230131 Jan 2023||Final version 7.2|
|8. Malignant disease and immunosuppression||20221231 Dec 2022||Final version 12.5|
|9. Nutrition and blood||20230303 Feb 2023||Final version 6.5|
|10. Musculoskeletal and joint diseases||20230331 Mar 2023||Final version 7.11|
|11. Eye||20230331 Mar 2023||Final version 5.5|
|12. Ear, nose and oropharynx||20220303 Feb 2022||Final version 5.0|
|13. Skin||20230131 Jan 2023||Final version 6.4|
|14. Immunological products and vaccines||On Hold|
|15. Anaesthesia||On Hold|
|GM formulary change log||20230331 Mar 2023|
|Wound care - complete||20201031 Oct 2020||Version 3.0|